Mary Szela, Abbott

Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

Jan van de Winkel, PhD, president and CEO of Genmab, the longtime innovation engine in antibody drug development, discusses its vision for adding a new business identity: commercial driver.

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

With a likely rate cut by the Federal Reserve this week, investors could rotate aggressively back to the sector.

Multi-region clinical trials can provide for varied results, but may not paint a full picture for a specific population.